RN1701 injection for treatment-resistant B-cell lymphomas
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This early-stage trial tests a new injection called RN1701 for B-cell lymphomas (blood cancers) that have not responded to or have returned after prior treatments. The study aims to see if this therapy can help patients whose cancer is difficult to treat.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–75 years old and able to give informed consent
- Diagnosed with one of these B-cell lymphomas: large B-cell, follicular, mantle-cell, or indolent lymphoma that has transformed; cancer cells must have CD19 and/or CD20 markers
- Cancer that is measurable on imaging (lymph nodes >1.5 cm or other tumors >1.0 cm)
- Cancer that has returned after or not responded to at least one prior treatment line (specific criteria vary by lymphoma type)
- Good overall health (ECOG performance status 0–1) with normal blood counts, liver, and kidney function
- No other active cancers, serious infections, or heart/lung/brain conditions; not pregnant or nursing
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called RN1701 for people with certain types of B-cell lymphoma that have come back or not responded to prior treatments. It aims to see if the drug is safe and effective.
This phase 1 trial tests an investigational treatment called RN1701 for people with certain types of B-cell lymphoma that have come back or not responded to previous therapies. The goal is to see if the drug is safe and effective.
This early-phase trial tests a new cell therapy called RS001 for people with certain B-cell blood cancers (lymphoma or leukemia) that haven't responded to other treatments. It aims to see if this personalized therapy can help when standard options have stopped working.
This trial tests a new treatment using specially engineered immune cells from a healthy donor to fight certain B-cell blood cancers that have come back or not responded to standard therapy. It aims to see if these cells can safely help patients achieve remission.
This Phase 1 study tests BRL-201 (an anti-CD19 treatment) for safety and early signs of effectiveness in adults with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. It may help people whose lymphoma has returned or not responded to prior treatments.
This trial studies a type of immune therapy called CD70-targeted CAR-T for people whose lymphoma has come back or did not respond after standard treatments. It may help by training your own T cells to recognize and attack lymphoma cells that carry the CD70 marker.
Hear when a new Relapsed/Refractory B-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.